B-type natriuretic peptide （BNP） and N-terminal proBNP （NT-proBNP）, the key members of natriuretic peptide family have been rec- ommended as the gold standard biomarkers for the diagnosis and prognosis of heart fa...B-type natriuretic peptide （BNP） and N-terminal proBNP （NT-proBNP）, the key members of natriuretic peptide family have been rec- ommended as the gold standard biomarkers for the diagnosis and prognosis of heart failure （HF） according to the current clinical guidelines. However, recent studies have revealed many previously unrecognized features about the natriuretic peptide family, including more accurate utilization of BNP and NT-proBNP in diagnosing HF. The pathophysiological mechanisms behind natriuretic peptide release, breakdown, and clearance are very complex and the diverse nature of circulating natriuretic peptides and fragments makes analytical detection particu- larly challenging. In addition, a new class of drug therapy, which works via natriuretic peptide family, has also been considered promising for cardiology application. Under this context, our present mini-review aims at providing a critical analysis on these new progresses on BNP and NT-proBNP with a special emphasis on their use in geriatric cardiology settings. We have focused on several remaining issues and chal- lenges regarding the clinical utilization of BNP and NT-proBNP, which include： （1） Different prevalence and diagnostic/prognostic values of BNP isoforms; （2） methodological issues on detection of BNP; （3） glycosylation of proBNP and its effect on biomarker testing; （4） specificity and comparability of BNP/NT-proBNP resulted from different testing platforms; （5） new development of natriuretic peptides as HF treatment modality; （6） BNP paradox in HF; and （7） special considerations of using BNP/NT-proBNP in elderly HF patients. These practical discussions on BNP/NT-proBNP may be instrumental for the healthcare providers in critically interpreting laboratory results and effective management of the HF patients.展开更多
文摘B-type natriuretic peptide （BNP） and N-terminal proBNP （NT-proBNP）, the key members of natriuretic peptide family have been rec- ommended as the gold standard biomarkers for the diagnosis and prognosis of heart failure （HF） according to the current clinical guidelines. However, recent studies have revealed many previously unrecognized features about the natriuretic peptide family, including more accurate utilization of BNP and NT-proBNP in diagnosing HF. The pathophysiological mechanisms behind natriuretic peptide release, breakdown, and clearance are very complex and the diverse nature of circulating natriuretic peptides and fragments makes analytical detection particu- larly challenging. In addition, a new class of drug therapy, which works via natriuretic peptide family, has also been considered promising for cardiology application. Under this context, our present mini-review aims at providing a critical analysis on these new progresses on BNP and NT-proBNP with a special emphasis on their use in geriatric cardiology settings. We have focused on several remaining issues and chal- lenges regarding the clinical utilization of BNP and NT-proBNP, which include： （1） Different prevalence and diagnostic/prognostic values of BNP isoforms; （2） methodological issues on detection of BNP; （3） glycosylation of proBNP and its effect on biomarker testing; （4） specificity and comparability of BNP/NT-proBNP resulted from different testing platforms; （5） new development of natriuretic peptides as HF treatment modality; （6） BNP paradox in HF; and （7） special considerations of using BNP/NT-proBNP in elderly HF patients. These practical discussions on BNP/NT-proBNP may be instrumental for the healthcare providers in critically interpreting laboratory results and effective management of the HF patients.
